The aim of the 19F MRI Imaging Agents for Disease Detection project is to develop new magnetic resonance (MR) molecular imaging strategies that will enable the in vivo monitoring of biological processes. Specifically, we will develop novel fluorinated polymers for imaging of early markers of diseases such as melanoma, prostate cancer, malignant glioma and Alzheimer’s disease. Specifically, the project involves the synthesis of new partly-fluorinated polymers having controlled architecture for the rapidly developing field of 19F MRI. Other imaging modalities, drugs and targeting ligands will be conjugated. The project aims to relate the structure of the macromolecules, determined carefully using advanced techniques such as NMR, light scattering, GPC, AFM and electron microscopy, to the performance as imaging agents. The agents will be tested in small animal (mouse) models of disease already developed by this group and our collaborators.
